NEW YORK (GenomeWeb) – Some cancers have become poster children for precision and personalized medicine, some have benefitted less so from advances in genomic testing, and others have been largely cutoff from the sea change of genomic medicine and molecular diagnostics.

Retinoblastoma has in some ways been both, having been one of the first cancers in which driving tumor suppressor gene mutations were discovered and are now tested for, but lacking genomic predictors of disease severity or response to drugs that can help personalize treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.